Format

Send to

Choose Destination
See comment in PubMed Commons below
Lancet Neurol. 2010 Jul;9(7):717-26. doi: 10.1016/S1474-4422(10)70105-8.

Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers.

Author information

1
Pathology Service, Massachusetts General Hospital, Boston, MA 02114, USA.

Abstract

Over the past 10 years, there has been an increasing use of molecular markers in the assessment and management of adult malignant gliomas. Some molecular signatures are used diagnostically to help pathologists classify tumours, whereas others are used to estimate prognosis for patients. Most crucial, however, are those markers that are used to predict response to certain therapies, thereby directing clinicians to a particular treatment while avoiding other potentially deleterious therapies. Recently, large-scale genome-wide surveys have been used to identify new biomarkers that have been rapidly developed as diagnostic and prognostic tools. Given these developments, the pace of discovery of new molecular assays will quicken to facilitate personalised medicine in the setting of malignant glioma.

PMID:
20610347
PMCID:
PMC3079431
DOI:
10.1016/S1474-4422(10)70105-8
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center